- Home
- NERV vs NRXP Comparison
NERV vs NRXP Comparison
Compare NERV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NRXP
- Stock Information
- Founded
- NERV 2007
- NRXP 2015
- Country
- NERV United States
- NRXP United States
- Employees
- NERV N/A
- NRXP N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- NRXP Health Care
- Exchange
- NERV Nasdaq
- NRXP Nasdaq
- Market Cap
- NERV 16.0M
- NRXP 14.8M
- IPO Year
- NERV 2014
- NRXP N/A
- Fundamental
- Price
- NERV $2.23
- NRXP $4.01
- Analyst Decision
- NERV Hold
- NRXP Strong Buy
- Analyst Count
- NERV 1
- NRXP 3
- Target Price
- NERV $5.00
- NRXP $31.67
- AVG Volume (30 Days)
- NERV 37.0K
- NRXP 2.8M
- Earning Date
- NERV 02-20-2025
- NRXP 11-14-2024
- Dividend Yield
- NERV N/A
- NRXP N/A
- EPS Growth
- NERV N/A
- NRXP N/A
- EPS
- NERV N/A
- NRXP N/A
- Revenue
- NERV N/A
- NRXP N/A
- Revenue This Year
- NERV N/A
- NRXP N/A
- Revenue Next Year
- NERV N/A
- NRXP N/A
- P/E Ratio
- NERV N/A
- NRXP N/A
- Revenue Growth
- NERV N/A
- NRXP N/A
- 52 Week Low
- NERV $2.06
- NRXP $1.10
- 52 Week High
- NERV $13.49
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- NERV 50.40
- NRXP 61.48
- Support Level
- NERV $2.07
- NRXP $3.20
- Resistance Level
- NERV $2.39
- NRXP $6.01
- Average True Range (ATR)
- NERV 0.12
- NRXP 0.95
- MACD
- NERV -0.01
- NRXP 0.11
- Stochastic Oscillator
- NERV 48.48
- NRXP 56.52
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.